기사 목록
-
Exostemtech, 'Adipose-derived Exosome' "Clinical Trial for OA in Next Year"
-
네오이뮨텍, 'PD-1 불응암' 타깃 허가임상 “내년 추진”
유료 -
엑소스템텍, '지방유래 엑소좀' "내년 퇴행성OA 임상"
유료 -
OliX Pharmaceuticals, 'GalNAc-siRNA platform' competitiveness against HBV∙NASH?
-
티카로스, 면역시냅스 강화 'CLIP CAR-T' "내년 임상"
유료 -
올릭스, 'GalNAc-siRNA 플랫폼' HBV∙NASH 경쟁력은?
유료 -
PeLeMed Develops the Low-Molecular Compound, What Are the Advantages of 'PeLeSeLect'?
-
3billion, 'variant interpretation+DB' for rare diseases.."Challenge for drug development"
유료 -
ENGAIN targets “Global medical devices” with “Polymer treatment agent”
-
엔게인, ‘고분자 치료소재’로 “글로벌 의료기기” 공략
-
Geninus, Single Cell Technology for precision medicine-from dignosis to drug discovery
-
Levatio's expanding strategy for cell and gene therapy with ‘circular RNA’
유료 -
쓰리빌리언, 희귀질환 '변이해석+DB' 강점.."신약도전"
유료 -
펠레메드, 저분자화합물 발굴 '펠레셀렉트' 장점은?
유료 -
BaobabAI, New Drug Development based on ‘Cryo-EM+Quantum Mechanics and AI’